Álvaro Zúñiga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Álvaro Zúñiga has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Pablo A. Rojas
Servicio de Urología, Complejo Asistencial Doctor Sótero del Río, Puente Alto, Chile
3 shared publications - Ignacio F. San Francisco
Departamento de Urología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
2 shared publications Alfredo Velasco
Servicio de Urología Clínica Santa María Santiago Chile
1 shared publication- Francisca Sepúlveda
Escuela de Pregrado, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
1 shared publication - Gabriela Vera
Servicio de Urología, Complejo Asistencial Doctor Sótero del Río, Puente Alto, Chile
1 shared publication Gonzalo Azocar
Servicio de Urología Clínica Santa María Santiago Chile
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in BMC Urology
Do young patients undergoing prostate cancer surgery have a worse prognosis? Oncologic outcomes in < 50 y/o prostate cancer post-radical prostatectomy
- 13 November 2026
- Published by Springer Nature in BMC Urology
Open AccessDo young patients undergoing prostate cancer surgery have a worse prognosis? Oncologic outcomes in < 50 y/o prostate cancer post-radical prostatectomy
- Open Access
- 11 March 2025
- Published by Instituto Mexicano del Seguro Social in Revista Chilena de Urología
- Vol. 90 (1) , 007-012
Experiencia en un centro nacional con ultrasonido focalizado de alta intensidad (HIFU) en el tratamiento del cáncer prostático
Antecedentes: El ultrasonido focalizado de alta intensidad (HIFU, high intensity focused ultrasound) es una alternativa de tratamiento para el cáncer ...
- 11 March 2025
- Published by Instituto Mexicano del Seguro Social in Revista Chilena de Urología
- Vol. 90 (1) , 007-012
Open AccessExperiencia en un centro nacional con ultrasonido focalizado de alta intensidad (HIFU) en el tratamiento del cáncer prostático
Antecedentes: El ultrasonido focalizado de alta intensidad (HIFU, high intensity focused ultrasound) es una alternativa de tratamiento para el cáncer ...
- Open Access
- 30 March 2021
- Published by Springer Nature in BMC Urology
- Vol. 21 (1) , 1-4
Protective role of intravesical BCG in COVID-19 severity
Objectives: To establish the role of BCG instillations in the incidence and mortality of COVID-19. Patients and methods: NMIBC patients in instillations with BCG (induction or maintenance) during 2019/2020 were included, establishing a COVID-19 group (with a diagnosis according to the national registry) and a control group (NO-COVID). The cumulative incidence (cases/total patients) and the case fatality rate (deaths/cases) were established, and compared with the national statistics for the same age group. T-test was used for continuous variables and Fisher's exact test for categorical variables. Results: 175 patients were included. Eleven patients presented CIS (11/175, 6.3%), 84/175 (48.0%) Ta and 68/175 (38.9%) T1. Average number of instillations = 13.25 ± 7.4. One hundred sixty-seven patients (95.4%) had complete induction. Forty-three patients (cumulative incidence 24.6%) were diagnosed with COVID-19. There is no difference between COVID-19 and NO-COVID group in age, gender or proportion of maintenance completed. COVID-19 group fatality rate = 1/43 (2.3%). Accumulated Chilean incidence 70–79 years = 6.3%. Chilean fatality rate 70–79 years = 14%. Conclusions: According to our results, patients with NMIBC submitted to instillations with BCG have a lower case-fatality rate than the national registry of patients between 70 and 79 years (2.3% vs. 14%, respectively). Intravesical BCG could decrease the mortality due to COVID-19, so instillation schemes should not be suspended in a pandemic.
- 30 March 2021
- Published by Springer Nature in BMC Urology
- Vol. 21 (1) , 1-4
Open AccessProtective role of intravesical BCG in COVID-19 severity
Objectives: To establish the role of BCG instillations in the incidence and mortality of COVID-19. Patients and methods: NMIBC patients in instillations with BCG (induction or maintenance) during 2019/2020 were included, establishing a COVID-19 group (with a diagnosis according to the national registry) and a control group (NO-COVID). The cumulative incidence (cases/total patients) and the case fatality rate (deaths/cases) were established, and compared with the national statistics for the same age group. T-test was used for continuous variables and Fisher's exact test for categorical variables. Results: 175 patients were included. Eleven patients presented CIS (11/175, 6.3%), 84/175 (48.0%) Ta and 68/175 (38.9%) T1. Average number of instillations = 13.25 ± 7.4. One hundred sixty-seven patients (95.4%) had complete induction. Forty-three patients (cumulative incidence 24.6%) were diagnosed with COVID-19. There is no difference between COVID-19 and NO-COVID group in age, gender or proportion of maintenance completed. COVID-19 group fatality rate = 1/43 (2.3%). Accumulated Chilean incidence 70–79 years = 6.3%. Chilean fatality rate 70–79 years = 14%. Conclusions: According to our results, patients with NMIBC submitted to instillations with BCG have a lower case-fatality rate than the national registry of patients between 70 and 79 years (2.3% vs. 14%, respectively). Intravesical BCG could decrease the mortality due to COVID-19, so instillation schemes should not be suspended in a pandemic.
- Open Access
- 8 November 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 530
Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up
The objective of this work was to assess the overall survival, cause-specific survival and biochemical failure-free survival of a contemporary cohort of patients with localized prostate cancer (PCa) treated with intensity-modulated radiation therapy (IMRT) or radical prostatectomy (RP).
- 8 November 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 530
Open AccessIntensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up
The objective of this work was to assess the overall survival, cause-specific survival and biochemical failure-free survival of a contemporary cohort of patients with localized prostate cancer (PCa) treated with intensity-modulated radiation therapy (IMRT) or radical prostatectomy (RP).